Reseachers discovered the drug that could be the new cure for lymphoma
In compliance with the FTC guidelines, please assume the following about all links, posts, photos and other material on this website: (...)
According to a study published in Cell Reports, researchers at Weill Cornell Medical College have shown in an experimental study that a drug may cure human lymphoma after only a few doses. If the results are confirmed in future studies then the discovery could be a major step forward in the treatment of lymphoma diffuse large B-cell lymphoma (DLBCL).
DLBCL, the most common form of non-Hodgkin lymphoma, usually occurs in people over 70 years and affects on average 7-8 people per 100 000 inhabitants. DLBCL is a cancer derived from B cells, which are part of the immune system and are responsible for producing antibodies.
In the newly published study, the researchers explained the role of the transcription factor Bcl6 in controlling genome: it seems that this transcription factor ensures the proliferation of this type of lymphoma. But what is interesting is that Bcl6 inhibitor can stop the proliferation of DLBCL. Dr. Ari Melnick, Gebroe Family Professor of Hematology / Oncology and the study’s senior investigator, they said urgently need a new strategy to treat this cancer because more and more patients become resistant to standard treatment.
Dr. Melnick began research on inhibitors BCl 9 years ago and improved the design of these drugs until they could use them to treat patients with cancer. It should be noted that Bcl6 is active in many types of cancers not only in leukemia, it is also active in breast cancer. In a study published in Nature Immunology, Dr. Melnick has shown that it is possible to turn off Bcl DLBCL without affecting their vital role in T cells and macrophages and that treatment has fewer side effects than standard chemotherapy. It must be said that this protein has long been considered too complex to be targeted because of its essential role in immune system function.
Transcription factors act through activation or inhibition of gene expression, however transcription regulatory factors master, like Bcl6, influence thousands of genes in several celltypes. Bcl6 can influence cell differentiation (in bone marrow) in either B cells, T cells or macrophages. In addition, Bcl6 controls an important stage of B cell development: more exactly the stage where they generate antibodies that destroy microorganisms. When B cells produce antibodies to fight off an infection, Bcl6 deactivates the DNA and stops the formation of RNA and proteins. When the infection was eradicated, Bcl6 does not influence the genome anymore; in DLBCL, however, Bcl6 remains attached to genes.
Forpost readings on Lymphoma research development please read the following :
Lymphoma Cells Shown to be Destroyed by Experimental Drug Combination